DE2362396A1 - 2,9-Dioxa-tricyclo/4,3,1,0/decan-4-ol carbamates - prepd. e.g. by reacting the 4-ol cpd. with an isocyanate - Google Patents

2,9-Dioxa-tricyclo/4,3,1,0/decan-4-ol carbamates - prepd. e.g. by reacting the 4-ol cpd. with an isocyanate

Info

Publication number
DE2362396A1
DE2362396A1 DE2362396A DE2362396A DE2362396A1 DE 2362396 A1 DE2362396 A1 DE 2362396A1 DE 2362396 A DE2362396 A DE 2362396A DE 2362396 A DE2362396 A DE 2362396A DE 2362396 A1 DE2362396 A1 DE 2362396A1
Authority
DE
Germany
Prior art keywords
methoxy
isocyanate
prepd
carbamates
dioxatricyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE2362396A
Other languages
German (de)
Other versions
DE2362396C2 (en
Inventor
Peter Willibrord Dr Thies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Kali Chemie Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE2306118A priority Critical patent/DE2306118C3/en
Application filed by Kali Chemie Pharma GmbH filed Critical Kali Chemie Pharma GmbH
Priority to DE2362396A priority patent/DE2362396C2/en
Publication of DE2362396A1 publication Critical patent/DE2362396A1/en
Application granted granted Critical
Publication of DE2362396C2 publication Critical patent/DE2362396C2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Carbamate of formula (I): (where a is a single or double bond; R1 is 1-4C alkyl; and one of R2 and R3 is H and the other is OCONHR5, R5 being an unsatd. aliphatic, cycloaliphatic or aromatic 1-6C residue), e.g., 4alpha-(N-alkylcarbamoyl)-3-methyl-10-methylene-8-methoxy-2,9-dio- xatricyclo 4.3.1.03,7 decane, are new cpds. They can be prepd. by the process of parent patent DT 2306118. Thus, the corresp. cpds. in which one of R2 and R3 is H and the other is OH may be reacted with R5NCO, an N-R5-carbamic acid ester or chloride, or with COCI2 followed by R5NH2. (I) has CNS depressant activity, being more active or less toxic than the corresp. cpds. in which R5 is a satd. alkyl.

Description

23623362362336

Hannover, 12. Dezember 1972 Z3-PA.MH/KaHanover, December 12, 1972 Z3-PA.MH/Ka

Patentanmeldung Carbamate der 4-Hydroxy-8- alkoxy-2t9-dioxatricycle» Patent application for carbamates of the 4-hydroxy-8-alkoxy-2 t 9-dioxatricycle »

Zusatz zu Patent (Patentanmeldung P 23 06 118.9)Addendum to patent (patent application P 23 06 118.9)

In der Patentanmeldung P 23 06 118.9 sind 4-Hydroxy-8-alkoxy-2,9-dioxatricyclof4,3,1,0^''Jdecane und deren Ester beschrieben mit folgender allgemeiner Formel:In the patent application P 23 06 118.9 are 4-hydroxy-8-alkoxy-2,9-dioxatricyclof4,3,1,0 ^ "Jdecane and their esters described with the following general formula:

in welcher R^ einen Alkylrest mit 1 bis 4 C-Atomen, R = OH, OCO-R, , OCONH-R5 bedeuten, wenn R-, Wasserstoff ist, und R, OCONH-R5 bedeutet, wenn Rp Wasserstoff ist, wobei R, für eine Alkylgruppe mit 1 bis 4 C-Atomen und R5 für Wasserstoff oder eine Alkylgruppe mit 1 bis 4 C-Atomen steht und die 10,11-Doppelbindung hydriert sein kann.in which R ^ is an alkyl radical with 1 to 4 carbon atoms, R = OH, OCO-R,, OCONH-R 5 when R- is hydrogen, and R, OCONH-R 5 is when Rp is hydrogen, where R 1 stands for an alkyl group with 1 to 4 carbon atoms and R 5 for hydrogen or an alkyl group with 1 to 4 carbon atoms and the 10,11 double bond can be hydrogenated.

Gegenstand der vorliegenden"Erfindung sind Carbamate der 4- Hydroxy-8-alkoxy-2,9-dioxatricyclor4,3,1 t0 Jdecane der allge meinen Formel IThe present invention relates to carbamates of 4-hydroxy-8-alkoxy-2,9-dioxatricyclor4.3.1 t 0 decanes of the general formula I.

5 09825/106 05 09825/106 0

= OCONHR5 bedeuin welcher R1 ein Alkylrest mit 1 bis 4 C-Atomen, OCONHR^, wenn R-, Wasserstoff ist, und
tet, wenn R2 Wasserstoff ist, wobei R^ für einen ungesättigten aliphatischen, cycloaliphatischen oder aromatischen Rest mit 1 bis 6 C-Atomen steht, und in der die 10,11-Doppelbindung hydriert sein kann.
= OCONHR 5 means in which R 1 is an alkyl radical with 1 to 4 carbon atoms, OCONHR ^, when R- is hydrogen, and
tet when R2 is hydrogen, where R ^ is an unsaturated aliphatic, cycloaliphatic or aromatic radical having 1 to 6 carbon atoms, and in which the 10,11 double bond can be hydrogenated.

Es wurde nämlich.überraschenderweise gefunden, daß durch Austausch der Alkylgruppe gegen aliphatische ungesättigte, cycloaliphatische oder aromatische Reste eine erhebliche Verbesserung der Wirkungsqualität erreicht wird. Das trifft sowohl für die α- wie für die ß-Verbindungen zu.It was found, surprisingly, that through exchange the alkyl group compared to aliphatic unsaturated, cycloaliphatic or aromatic radicals a considerable improvement the quality of effect is achieved. This applies to both the α and the ß compounds.

So wirken beispielsweise schon die Allylcarbaminsaureester der 10,11 -nicht hydrierten, wie auch der 10,11 -hydrierten Verbindung der vorgenannten Formel I sehr viel intensiver ZNS-dämpfend oder sie sind weniger toxisch als die entsprechenden n-Propylcarbaminsäureester, wie aus der nachfolgenden Tabelle 1 hervorgeht .For example, the allylcarbamic acid esters of the 10,11 -non hydrogenated, as well as the 10,11 -hydrogenated compound the aforementioned formula I very much more intensive CNS-dampening or they are less toxic than the corresponding n-propylcarbamic acid esters, as can be seen in Table 1 below.

509 8 25/1060509 8 25/1060

ORiGfNAL INSPECTEDORiGfNAL INSPECTED

— 3 — Tabelle- 3 - table

0-CO-NH-R0-CO-NH-R

OCONHROCONHR

-CH2-CH2-CH3 -CH 2 -CH 2 -CH 3

CH2-CH=CHCH 2 -CH = CH

CH2-CH2-CH3 CH 2 -CH 2 -CH 3

CH0-CH=CH0 CH 0 -CH = CH 0

LD1-Q p.o. MausLD 1 -Q po mouse

D150 i.p. Maus
Ptosis Maus
D 150 ip mouse
Ptosis mouse

verminderte Motilität Mausdecreased mouse motility

Seitenlage (Narkose) Maus Lateral position (anesthesia) mouse

Haffner Reflex
fehlt Maus
Haffner reflex
missing mouse

619 mg/kg619 mg / kg

516 mg/kg 100 mg/kg516 mg / kg 100 mg / kg

100 mg/kg 100 mg/kg 200 mg/kg100 mg / kg 100 mg / kg 200 mg / kg

970 mg/kg970 mg / kg

444 mg/kg 50 mg/kg444 mg / kg 50 mg / kg

50 mg/kg50 mg / kg

50 mg/kg50 mg / kg

100 mg/kg100 mg / kg

327 mg/kg327 mg / kg

244 mg/kg
100 mg/kg
244 mg / kg
100 mg / kg

50 mg/kg
100 mg/kg
100 mg/kg
50 mg / kg
100 mg / kg
100 mg / kg

339 mg/kg339 mg / kg

279 mg/kg 100 mg/kg279 mg / kg 100 mg / kg

25 mg/kg 100 mg/kg 100 mg/kg25 mg / kg 100 mg / kg 100 mg / kg

Das im Beispiel 6 beschriebene 4ß-Phenylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricycloC4,3,1,0 ' Udecari zeigt als . ß-Verbindung keine narkotische Wirkung, jedoch eine Wirkung auf das Nervensystem, die an der weißen Maus als analgetisch (ED50= 140 mg/kg; LD 1500 mg/kg p.o.), muskelrelaxierend (vergleichbar mit Phenobarbital!) und spasmolytisch (ED =0,1 Papaverin und 0,2 ED100 Atropin) erfaßt werden konnten.The 4β-phenylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricycloC4,3,1,0 'Udecari described in Example 6 shows as. ß-compound no narcotic effect, but an effect on the nervous system, which in the white mouse as analgesic (ED 50 = 140 mg / kg; LD 1500 mg / kg po), muscle relaxant (comparable to phenobarbital!) and spasmolytic (ED = 0.1 papaverine and 0.2 ED 100 atropine) could be detected.

50982 5/1050982 5/10

Die Herstellung der erfindungsgemäßen Carbamate erfolgt wie in der Stammanmeldung P 23 06 118 beschrieben. Die Veresterung der OH-Gruppe in 4-Stellung kann auf bekannte Weise mit einem Isocyanat der allgemeinen Formel R NCO erfolgen, worin FU dieThe carbamates according to the invention are prepared as in the parent application P 23 06 118 described. The esterification of the OH group in the 4-position can be carried out in a known manner with a Isocyanate of the general formula R NCO take place, where FU the

oben angegebene Bedeutung hat. Es ist auch möglich, die OH-Verbindung mit einem entsprechend substituierten Carbaminsäureester oder -chlorid umzusetzen. Die Herstellung der erfindungsgemäßen Carbamate über Phosgen erfolgt durch Reaktion der 4-Hydroxy-8-alkoxy-2,9-dioxatricyclo£4, 3,1,0 ' J decane mit Phosgen zum Chlorameisensäureester, aus dem durch Umsetzung mit dem entsprechenden Amin R1-NH0 das gewünschte Carbamat erhalten wird.has the meaning given above. It is also possible to react the OH compound with an appropriately substituted carbamic acid ester or chloride. The carbamates according to the invention are prepared via phosgene by reacting the 4-hydroxy-8-alkoxy-2,9-dioxatricyclo £ 4, 3,1,0 'I decane with phosgene to give the chloroformic acid ester, from which by reaction with the corresponding amine R 1 -NH 0 the desired carbamate is obtained.

509825/ 1.060509825 / 1.060

Beispiel 1example 1

4a-N"-Allylcarbaminoyl-3-methyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1,0 ' Idecan4a-N "-Allylcarbaminoyl-3-methyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1,0 'Idecan

5 g 4α-Hydroxy-3-methyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1 ,Cr* ' ]decan und 6,5 g Allylisocyanat in 70 ml trockenem Benzol gelöst,wurden 24 Stunden am Rückfluß erhitzt. Dann wurde das Reaktionsgemisch zunächst ■ im Vakuum eingedampft, der Rückstand zur Entfernung von überschüssigem Allylisocyanat mit 50 ml Äthanol versetzt und erneut im Vakuum eingeengt. Danach wurde mit 150 ml · Wasser aufgenommen und 4 χ mit 100 ml Äther extrahiert. Die vereinigten Ätherphasen wurden über Magnesiumsulfat getrocknet, mit etwas Kohle geklärt und nach Filtration im Vakuum eingedampft. Es resultierten 7,5 g kristallines Rohprodukt, Nach Umkristallisieren' aus Äther/Hexan (1:9; V/V) wurden 4,5 g weiße Kristalle erhalten (71,5 % der Theorie). .5 g of 4α-hydroxy-3-methyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1, Cr * '] decane and 6.5 g of allyl isocyanate dissolved in 70 ml of dry benzene were 24 Heated at reflux for hours. The reaction mixture was then first evaporated in vacuo, the residue was treated with 50 ml of ethanol to remove excess allyl isocyanate and again concentrated in vacuo. It was then taken up with 150 ml · water and extracted 4 with 100 ml ether. The combined ether phases were dried over magnesium sulfate, clarified with a little charcoal and, after filtration, evaporated in vacuo. 7.5 g of crystalline crude product resulted. After recrystallization from ether / hexane (1: 9; V / V), 4.5 g of white crystals were obtained (71.5 % of theory). .

15215, M = 295,35 15215 , M = 295.35

Fp. 98-1010C (Kofier, unkorrigiert) [α] ψ + 38 ° (Methanol)Mp. 98-101 0 C (Kofier, uncorrected) [α] ψ + 38 ° (methanol)

509825/1060509825/1060

Beispiel 2Example 2

4ß-N-Allylcart)aminoyl-3-niethyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1,0^''Jdecan 4β-N-Allylcart) aminoyl-3-diethyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1,0 ^ "decane

5 g 4ß-Hydroxy-3-methyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1,0 ''Jdecan wurden zunächst analog Beispiel 1 mit Allylisocyanat in Benzol umgesetzt und bearbeitet. Es wurden erhalten: 7,5 g öliges Rohprodukt. Dieses konnte erst nach Chromatographie an 100 g Kieselgel mit CCl^/CHCl^ (80:20; V:V) so rein erhalten werden, daß es kristallisierte. Ausbeute: 5,0 g weiße Kristalle (79,3 % der Theorie). C15H21NO5, M = 295,35
Fp. 52-530C (Kofier, unkorrigiert) [cc] Jp + 46 ° (Methanol)
5 g of 4β-hydroxy-3-methyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1,0 "decane were first reacted and processed with allyl isocyanate in benzene as in Example 1. The following were obtained: 7.5 g of an oily crude product. This could only be obtained so pure after chromatography on 100 g of silica gel with CCl ^ / CHCl ^ (80:20; V: V) that it crystallized. Yield: 5.0 g of white crystals (79.3 % of theory). C 15 H 21 NO 5 , M = 295.35
Mp. 52-53 0 C (Kofier, uncorrected) [cc] Jp + 46 ° (methanol)

Beispiel "5Example "5

4oc-N-Allylcarbaminoyl-3,10~dimethyl-8-methoxy-2,9-dioxatricyclo[4,3,1,O3 ' 7Jdecan 4oc-N-Allylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1, O 3 ' 7 i-decane

4,53 4a-Hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatrieyclo-[4,3,1jO ' Jdecan wurden mit 4 g Allylisocyanat in Benzol unter Zugabe weniger Tropfen Eisessig 24 Stunden bei 50 600C erhitzt und danach analog Beispiel 1 aufgearbeitet.4.53 4-hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatrieyclo- [4,3,1jO 'Jdecan were mixed with 4 g of allyl isocyanate in benzene with addition of a few drops of glacial acetic acid for 24 hours at 50 60 0 C. heated and then worked up analogously to Example 1.

Nach Umkristallisation des Rohproduktes (6,0 g) aus n-Hexan/ Diäthyläther (1:9; V:V) wurden 4,2 g weißes Kristallisat erhalten (67 % der Theorie).After recrystallization of the crude product (6.0 g) from n-hexane / diethyl ether (1: 9; V: V) 4.2 g of white crystals were obtained (67 % of theory).

C15H23NO5 , M = 297,35C 15 H 23 NO 5 , M = 297.35

Fp 56 - 58 ° C (Kofier, unkorrigiert)Mp 56 - 58 ° C (Kofier, uncorrected)

LaJ D2 " 32 ° (Methano1)L a JD 2 " 32 ° ( Methano1 )

509825/1060509825/1060

Beispiel. 4Example. 4th

4cx-N-Cyclohexylcarbaminoyl-3,1O-dimethyl-8-methoxy-2,9-dioxatricyclo[4,3,1>0^''Jdecan 4cx -N-Cyclohexylcarbaminoyl-3,1O-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1> 0 ^ "decane

5 g 4a-Hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1,0 ''Jdecan wurden mit 5 g Cyclohexyl!socyanat in 70 ml Benzol unter -Zugabe von 3 Tropfen Eisessig 6 Stunden unter Rückfluß gekocht» Es wurde analog Beispiel 1 aufgearbeitet. Das zunächst ölig angefallene Rohprodukt konnte aus η-Hexan kristallisiert werden. Ausbeute: 6,2 g (das sind 78 % der Theorie).5 g of 4-hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1, 0 '' Jdecan were mixed with 5 g of cyclohexyl! Diisocyanate in 70 ml of benzene under addition was of 3 drops of glacial acetic acid Boiled under reflux for 6 hours. Work-up was carried out as in Example 1. The initially oily crude product could be crystallized from η-hexane. Yield: 6.2 g (that is 78 % of theory).

Weiße Kristalle, C18H29NO5, M = 339,43 · .White crystals, C 18 H 29 NO 5 , M = 339.43 ·.

Fp. 109-1100C (Kofier, unkorrigiert) [a] Q1 - 26 ° (Methanol)-Mp. 109-110 0 C (Kofier, uncorrected) [a] Q 1 - 26 ° (methanol) -

Beispiel 5Example 5

4α-Cyclohexylcarbaminoyl-3-methyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1,05j7]decan ·4α-Cyclohexylcarbaminoyl-3-methyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1,0 5j7 ] decane ·

6,5 g ^a-Hydroxy-J-methyl-IO-methylen-e-methoxy-E^-dioxatricyclo [4,3,1,0 ''Jdecan wurden in Benzol mit 15 g Cyclohexylisocyanat analog Beispiel 4 umgesetzt und aufgearbei- ■ tet. Da das Endprodukt jedoch nicht kristallisiert werden · konnte, wurde eine Reinigung durch Chromatographie an Kieselgel auf Dickschichtplatten vorgenommen, (17 Platten 20 χ 20; Fließmittel: η-Hexan, Essigsäufeäthylester, n-Propanol 70 : 24 : 6; V : V : V)
Ausbeute: 5,5 g farbloses öl, das sind 59 % der Theorie.
6.5 g of a-hydroxy-J-methyl-IO-methylen-e-methoxy-E ^ -dioxatricyclo [4,3,1,0 "decane were reacted in benzene with 15 g of cyclohexyl isocyanate as in Example 4 and worked up ■ tet. However, since the end product could not be crystallized, it was purified by chromatography on silica gel on thick-layer plates (17 plates 20 χ 20; mobile phase: η-hexane, ethyl acetate, n-propanol 70: 24: 6; V: V: V )
Yield: 5.5 g of a colorless oil, that is 59 % of theory.

C18H27NO5 , M = 337,40C 18 H 27 NO 5 , M = 337.40

[ctj ^1 + 62 ° (Methanol) .[ctj ^ 1 + 62 ° (methanol).

609825/10 60609825/10 60

Beispiel 6Example 6

4ß-N-Phenylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1,03' 7].decan4SS-N-Phenylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1,0 3 '7] .decan

3,4 g 4ß-Hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo[4,3,1»0 ' Jdecan und 5»13 g Phenylisocyanat wurden in 200 ml Benzol, das mit 10 Tropfen Eisessig versetzt war, gelöst und 15 Minuten auf 160C erhitzt. Danach wurde auf Raumtemperatur abgekühlt und 24 Stunden stehengelassen. Anschließend wurde im.Vakuum eingeengt und analog Beispiel 1 aufgearbeitet.3.4 g of 4ß-hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1 »0 'i-decane and 5» 13 g of phenyl isocyanate were dissolved in 200 ml of benzene with 10 drops of glacial acetic acid was added, dissolved and heated to 16 0 C for 15 minutes. It was then cooled to room temperature and left to stand for 24 hours. The mixture was then concentrated in a vacuum and worked up analogously to Example 1.

Nach Umkristallisation aus Benzol wurden 4,1 g weißes Kristallisat erhalten, das sind 79 % der Theorie.After recrystallization from benzene, 4.1 g of white crystals were obtained, that is 79 % of theory.

C18H23NO5 ,M= 333,3C 18 H 23 NO 5 , M = 333.3

Fp. 154 -156 ° C (Kofier, unkorrigiert) . · ja] ^0 + 17° (Methanol)Mp 154-156 ° C (Kofier, uncorrected). Yes] ^ 0 + 17 ° (methanol)

509825/106 0509825/106 0

Claims (1)

PatentanspruchClaim 1..) 2,9-Dioxatricyclo[4,3,1,0 ]decane der allgemeinen Formel I1 ..) of 2,9-dioxatricyclo [4,3,1, 0] decanes of the general formula I in welcher R. ein Alkylrest mit 1 bis 4 C-Atomen, EL· = OCONHR5, wenn R3 Wasserstoff ist, und R3 = OCONHR5 bedeutet, wenn Rp Wasserstoff ist, wobei R5 für einen ungesättigten aliphatischen, cycloaliphatischen oder aromatischen Rest mit 1 bis 6 C-Atomen steht, und in der die 10,11-Doppelbindung hydriert sein kann. in which R. is an alkyl radical with 1 to 4 carbon atoms, EL = OCONHR 5 when R 3 is hydrogen, and R 3 = OCONHR 5 when Rp is hydrogen, where R 5 is an unsaturated aliphatic, cycloaliphatic or aromatic Radical with 1 to 6 carbon atoms, and in which the 10,11 double bond can be hydrogenated. 509825/1060509825/1060
DE2362396A 1973-02-08 1973-12-15 3-methyl-10-methylene-2,9-dioxatricyclo [4,3,1,0 → 3 →, → 7 →] decane Expired DE2362396C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE2306118A DE2306118C3 (en) 1973-02-08 1973-02-08 S-methyl-10-methylene ^ -dioxatricyclo [43,1,037I decane and 3,10-dimethyl2,9-dioxatricyclo [43,1,03 · 7! decane and processes for their production
DE2362396A DE2362396C2 (en) 1973-02-08 1973-12-15 3-methyl-10-methylene-2,9-dioxatricyclo [4,3,1,0 → 3 →, → 7 →] decane

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2306118A DE2306118C3 (en) 1973-02-08 1973-02-08 S-methyl-10-methylene ^ -dioxatricyclo [43,1,037I decane and 3,10-dimethyl2,9-dioxatricyclo [43,1,03 · 7! decane and processes for their production
DE2362396A DE2362396C2 (en) 1973-02-08 1973-12-15 3-methyl-10-methylene-2,9-dioxatricyclo [4,3,1,0 → 3 →, → 7 →] decane

Publications (2)

Publication Number Publication Date
DE2362396A1 true DE2362396A1 (en) 1975-06-19
DE2362396C2 DE2362396C2 (en) 1982-08-05

Family

ID=32963212

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2306118A Expired DE2306118C3 (en) 1973-02-08 1973-02-08 S-methyl-10-methylene ^ -dioxatricyclo [43,1,037I decane and 3,10-dimethyl2,9-dioxatricyclo [43,1,03 · 7! decane and processes for their production
DE2362396A Expired DE2362396C2 (en) 1973-02-08 1973-12-15 3-methyl-10-methylene-2,9-dioxatricyclo [4,3,1,0 → 3 →, → 7 →] decane

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2306118A Expired DE2306118C3 (en) 1973-02-08 1973-02-08 S-methyl-10-methylene ^ -dioxatricyclo [43,1,037I decane and 3,10-dimethyl2,9-dioxatricyclo [43,1,03 · 7! decane and processes for their production

Country Status (1)

Country Link
DE (2) DE2306118C3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2730988A1 (en) 1977-07-08 1979-01-25 Kali Chemie Pharma Gmbh 3-Azido-methyl-2,9-di:oxa-tri:cyclo-decane derivs. - useful as analgesic, antipyretic and antiphlogistic agents

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2607106C2 (en) 1976-02-21 1986-01-16 Kali-Chemie Pharma Gmbh, 3000 Hannover 2,9-Dioxatricyclo [4,3,1,0 → 3 → →, → → 7 →] decane and process for their preparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1961433A1 (en) * 1969-12-08 1971-06-16 Kali Chemie Ag 3,10-Dioxatricyclo- (2,2,2,22,6?) - decane and process for their preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1961433A1 (en) * 1969-12-08 1971-06-16 Kali Chemie Ag 3,10-Dioxatricyclo- (2,2,2,22,6?) - decane and process for their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GB-Z: Tetrahedron Letters, Nr. 35, 1970, 3087-90 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2730988A1 (en) 1977-07-08 1979-01-25 Kali Chemie Pharma Gmbh 3-Azido-methyl-2,9-di:oxa-tri:cyclo-decane derivs. - useful as analgesic, antipyretic and antiphlogistic agents

Also Published As

Publication number Publication date
DE2306118A1 (en) 1974-08-15
DE2306118B2 (en) 1980-02-07
DE2362396C2 (en) 1982-08-05
DE2306118C3 (en) 1980-10-16

Similar Documents

Publication Publication Date Title
DE2560633C2 (en)
DE1159462B (en) Process for the preparation of s-triazine derivatives
DE3235933A1 (en) Process for the preparation of bicyclic orthoester amides
DE2629657A1 (en) PROCESS FOR THE CARBAMOYLATION OF PHENOLIC HYDROXY GROUPS FOR THE PRODUCTION OF PHENOLIC N-DISUBSTITUTED CARBAMATE STARS AND THE ION PAIR SOLUTIONS USED THEREFORE
DE2362396A1 (en) 2,9-Dioxa-tricyclo/4,3,1,0/decan-4-ol carbamates - prepd. e.g. by reacting the 4-ol cpd. with an isocyanate
DE1668425A1 (en) Process for the preparation of diorganoantimony acylates
DE1227914B (en) Process for the preparation of 3- (1, 2-dithia-cyclopentyl) -5-pentanoic acid
EP0087585A1 (en) Method for the preparation of 3-alkoxy-acrylonitriles
DD141158A1 (en) PROCESS FOR THE PREPARATION OF NEW ARYLAMINOIMIDAZOLINE DERIVATIVES
CH497408A (en) Testosterone derivs having androgenic-anabolic activity
DE2446256B2 (en) PROCESS FOR THE MANUFACTURING OF HEXAHYDROTHIENO SQUARE CLAMP ON 3.4-SQUARE BRACKET TO -IMIDAZOLE-2,4-DIONENE
DD144051A5 (en) PROCESS FOR THE PREPARATION OF ISOCYANATES
DE2331044A1 (en) DIPHENYLMETHANE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
DE2351556C2 (en) Process for the preparation of N-haloformyl-carbamic acid halides
DE2613306C2 (en)
DE2065698A1 (en) PROCESS FOR THE PREPARATION OF 2ISOPROPYL-6-METHYL-4 (3H) -PYRIMIDONE
EP0560158A2 (en) Process for the preparation of beta-aminoacrylic acid esters
DE2509780A1 (en) TRIS- (2-HYDROXYARYL) -CYANURIC ACID ESTER
DE3150918C1 (en) Process for the preparation of anilides in the ergoline series
DE1953059C (en) Carbamic acid derivatives
DE1770183A1 (en) New tertiary ester salts and processes for making the same
DE1158499B (en) Process for the production of isonitriles
DE1953059A1 (en) Carbamic acid derivatives and processes for making the same
DE1247294B (en) Process for the preparation of 2-chloro-3-oxobutyric acid amides
DE1695757C3 (en) Pyridine methanol carbamates and processes for their preparation

Legal Events

Date Code Title Description
OD Request for examination
8126 Change of the secondary classification

Ipc: ENTFAELLT

AF Is addition to no.

Ref country code: DE

Ref document number: 2306118

Format of ref document f/p: P

D2 Grant after examination
8340 Patent of addition ceased/non-payment of fee of main patent